Elinzanetant Leads To a Significantly Lower Frequency of Vasomotor Symptoms Associated with Endocrine Therapy for HR-positive Breast Cancer By Ogkologos - June 11, 2025 551 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the OASIS-4 study Source RELATED ARTICLESMORE FROM AUTHOR No OS Improvement with CDK4/6 Inhibitors Used in First- Compared with Second-Line Treatment in Patients with HR-positive, HER2-negative ABC Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe MOST POPULAR Minimizing Time Between Diagnosis and End of Treatment Improves Breast Cancer... July 5, 2021 Qué debo saber sobre la mastectomía con cierre plano después de... January 17, 2024 Researchers Create Modified Antibodies to Target RAS and p53 in Cancer April 2, 2021 Cancer in My Community: Accessing Care Through the Public Health System... May 9, 2023 Load more HOT NEWS Adding Atezolizumab to First-Line Bevacizumab Plus Platinum Regimen Improves Survival in... FDA Approves Selinexor for Relapsed/Refractory Diffuse Large B-Cell Lymphoma Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... New Generation of Antibody-Drug Conjugates (ADCs) Shows Unprecedented Promise in Early-Stage...
